Presentations
LATEST COMPANY PRESENTATIONS AND INTERVIEWS
Newly appointed CEO, Gustav H. Gram, hosts a Q&A with Stokk.io on PILA PHARMA’s changes with Founder Dorte X. Gram transitioning to Chairman of the Board and what changes and direction that investors can expect. The Q&A is conducted in English together with Anders Egsvang from Stokk.io
Please, find the link to the video (in English) here
(22 April-2024)
Aktiespararna Online Lifescience Day (ONLINE / Stockholm, Sweden)
Please, find the link to the video (in English) here
(17 April-2024)
Dansk Aktionærforening Fyn [INVESTOR DAGEN] (Odense, Denmark)
Please, find the link to the video (in English) here
(16 April-2024)
Redeye Online Investor Event (ONLINE / Stockholm, Sweden)
Please, find the link to the video (in English) here
(11 April-2024)
AktieInfo Investor Evening (Scandic Sydhavnen, Copenhagen, Denmark)
Please, find the link to the video (in Danish) here
(21 March-2024)
Q&A on PILA PHARMA’s Q4 report and the outlook for 2024 with PILA PHARMA’S innovative take on an alternative route to treating obesity, diabetes and cardiovascular disease together with Anders Egsvang from Stokk.io
Please, find the link to the video (in English) here
(28 February-2024)
PIla Pharma CEO Dorte X. Gram discusses with financial markets expert Richard Busellato on the obesity market, considerations of investing in pharma and how future solutions could look like including Pila Pharma’s novel tablet based #TRPV1-antagonist treatment
Please, find the link to the video (in English) here
(01 December-2023)
Our CEO Dorte X. Gram presented the Company and ongoing Rights Issue at Aktiespararna event Stora Aktiedagen i Stockholm
Please, find the link to the video (in English) here
(27 November-2023)
Our CEO Dorte X. Gram presented the Company and ongoing Rights Issue to the Danish young-investor group “Unge Investorer”
Please, find the link to the video (in Denish) here
(27 November-2023)
Our CEO Dorte X. Gram presents at Redeye Life Science Day 2023
Please, find the link to the video (in English) here
(23 November-2023)
Proinvestor – Pila Pharma vil lave en tablet mod fedme og diabetes
En mere teknisk introduktion til PILA PHARMA
For more information, please visit the following link here
(16 November-2023)
Today we paid a visit to the impressive clinical site in Cambridge where we plan to carry out our next phase 2 trial with XEN-D0501 in obese people with diabetes.
Happy worlddiabetesday to all!
Please, find the link to the video (in English) here
(14 November-2023)
CEO & Founder Dorte X. Gram presents PILA PHARMA’s innovative take on an alternative route to treating obesity, diabetes and cardiovascular disease at the LSX Inv€$tival conference in London.
Please, find the link to the video (in English) here
(13 November-2023)
Dansk Aktionærforening: Kom med på rejsen mod mere effektiv fedmebehandling
En god introduktion til PILA PHARMA
For more information, please visit the following link here
(07 November-2023)
Presentation by PILA PHARMA CEO, Dr. Dorte X. Gram at the LSXNordic Congress on 11/10/2023 on the case of TRPV1 antagonist XEN-D0501 as a novel treatment of obesity and type-2 diabetes.
In the presentation, Dr. Gram presents some previously undisclosed data on a heartfailure marker (ANP) further strengthening the case for XEN-D0501 as a safe and potent molecule for its class with benificial cardiometabolic effects.
(19 Oct-2023)
(03 Oct-2023)
(29 Sep-2023)
On August 28, 2023 in Finans Stockholm, our CEO For Dorte X Gram gave some hints at how PILA PHARMA will proceed and be relevant with our TRPV1 antagonist treatment.
Please, find the link to the video (in English) here
(07 Sep-2023)
CEO of Pila Pharma, Dorte X. Gram, interviews Matt Sondag about the thoughts and challenges of a living with erythromelalgia, a rare disease with periods of intense pain.
Please, find the link to the video (in English) here